Literature DB >> 3423739

Fibroblast growth-stimulatory activity released from human monocytes. The contribution of tumour necrosis factor.

R Austgulen1, T Espevik, J Nissen-Meyer.   

Abstract

Human monocytes release fibroblast growth-stimulatory activity. In this study tumour necrosis factor (TNF) has been identified as a major contributor to the monocyte-derived fibroblast growth-stimulatory activity. A neutralizing monoclonal antibody (MoAb) against recombinant TNF (rTNF) inhibited growth of FS-4 fibroblasts and skin biopsy fibroblasts induced by monocyte supernatants, indicating that TNF was involved in the stimulation. Optimal growth of FS-4 fibroblasts was induced by monocyte supernatants at dilutions which contained TNF at a concentration between 1.6 X 10(-6) and 4.0 X 10(-5) micrograms/ml, less growth being induced at higher TNF concentrations. Contrary to this, no optimal concentration interval was found for rTNF, since increasing rTNF concentrations always resulted in increased growth stimulation. It also appeared that natural TNF in the monocyte supernatants induced growth at a much lower concentration than rTNF tested in the absence of monocyte supernatant.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3423739     DOI: 10.1111/j.1365-3083.1987.tb02297.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  4 in total

1.  Pulmonary inflammation and fibrosis in a murine model of asbestosis and silicosis. Possible role of tumor necrosis factor.

Authors:  E Bissonnette; M Rola-Pleszczynski
Journal:  Inflammation       Date:  1989-06       Impact factor: 4.092

2.  The effect of Mycobacterium tuberculosis on the susceptibility of human cells to the stimulatory and toxic effects of tumour necrosis factor.

Authors:  E A Filley; H A Bull; P M Dowd; G A Rook
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

3.  Stimulation of fibroblast chemotaxis by human recombinant tumor necrosis factor alpha (TNF-alpha) and a synthetic TNF-alpha 31-68 peptide.

Authors:  A E Postlethwaite; J M Seyer
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

4.  A Pilot Study on Ocular Safety and Efficacy of Infliximab as an Antifibrotic Agent After Experimental Glaucoma Filtration Surgery.

Authors:  Eleni Nikita; Alexandre Moulin; Ioannis Vergados; Dimitrios Brouzas; Panagiotis G Theodossiadis
Journal:  Ophthalmol Ther       Date:  2017-07-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.